Mustang Bio Inc logo

Mustang Bio Inc(MBIO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.42
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MBIO

11/13/2026: MBIO (1-star) is currently NOT-A-BUY. Pass it for now.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for difficult-to-treat cancers and rare genetic diseases. Its main strengths lie in promising clinical pipeline assets like MB-106 and strategic partnerships with premier research institutions. The primary growth story centers on positive clinical trial readouts advancing toward potential commercialization or lucrative licensing agreements. However, the company faces substantial execution, dilution, and financing risks typical of pre-revenue biotechnology firms. The stock is best suited for speculative growth investors willing to monitor clinical data catalysts and regulatory updates closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company lacks commercial revenue growth, relying instead on high-risk clinical trial progress.
Momentum investorStrong fit while signal remains positiveLow-float clinical-stage biotech stocks can experience sharp short-term momentum spikes on positive trial data announcements.
Value investorWeak fitPre-revenue financials and continuous cash burn make traditional valuation metrics inapplicable.
Dividend investorWeak fitMustang Bio pays no dividends and retains all capital for research.
Low-risk investorWeak fitHigh share price volatility and binary clinical outcome risks create substantial downside exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow market capitalization and clinical-stage status drive high intraday and historical price swings.
Valuation riskHighValuations are speculative and vulnerable to shifts in market sentiment toward early-stage biotech.
Competition risk (clinical oncology and cell therapy competition)Medium / highLarger pharmaceutical competitors may outpace Mustang Bio in bringing similar cell therapies to market.
Business qualityMediumThe company features promising academic partnerships but lacks an established commercial product foundation.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess depends heavily on complex manufacturing processes and navigating unpredictable clinical trial outcomes.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.20M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 42.2K shares
Beta 2.2
52 Weeks Range 0.35 - 1.43
Updated Date 11/15/2026
52 Weeks Range 0.35 - 1.43
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.51

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -18.31%
Avg. Invested days 6
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MBIO receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
MBIO has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+87.8%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
MBIO's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is MBIO's strongest growth driver at +87.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+53.9%, strong) is also strong, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 9.5% (soft) and 92.0% of outstanding shares are publicly tradable (strong). Insider ownership of 8.01% supports management-shareholder alignment.

Top 5 Institutional Investors

Kestra Advisory Services, LLC 2.60%
BlackRock Inc 1.12%
Citadel Advisors Llc 0.78%
Geode Capital Management, LLC 0.56%
CFO4Life Group, LLC 0.44%

Unit Economics (Per $1K Revenue)

★★★★★
MBIO generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
MBIO has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Cell and Gene Therapy Pipeline Licensing and CommercializationFuture potential milestone payments, product sales, and out-licensing royalties from developed immunotherapies.Mustang Bio is currently pre-revenue and does not yet sell commercial medical products.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -14.07M
Price to Sales(TTM) 2205.73
Enterprise Value -14.07M
Price to Sales(TTM) 2205.73
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.14
Shares Outstanding 6.74M
Shares Floating 6.20M
Shares Outstanding 6.74M
Shares Floating 6.20M
Percent Insiders 8.01
Percent Institutions 9.49

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.